Textbook of Personalized Medicine - Second Edition [2015]

710 Alzheimer’s disease (AD) (cont.) hypertension , 493 LOAD susceptibility gene , 420 molecular imaging , 601–602 protein misfo ...

711 PCR biochip technology , 47–48 protein biochips developments in , 55 for personalized medicine , 55–56 ProteinChip , 53–54 p ...

712 Body time (BT) , 181 Bortezomib , 333 BRACAnalysis Rearrangement Test (BART) , 298 Brain cancer management biosimulation app ...

713 predictive markers , 221 VeraTag™ assay system , 223 brain tumors ( see Brain cancer management) breast cancer ( see Breast ...

714 Cancer therapy (cont.) pancreatic cancer ( see Pancreatic cancer) PI3K-AKT pathway , 236 PREDICT consortium , 370 prostate c ...

715 Center for Applied Genomics and Precision Medicine , 616 Center for Genomic and Computational Biology , 616, 617 Center of H ...

716 CUB domain-containing protein 1 (CDCP1) , 233 Current Procedural Terminology (CPT) codes , 629 Cyclodextrin-modifi ed micell ...

717 asthma , 515 CF , 548 CFS , 455 colorectal cancer , 338 GxE interactions , 23 Huntington disease , 424 lung function and anc ...

718 Gastrointestinal stromal tumors (GISTs) , 215, 226 Gaucher’s disease , 538 GBM. See Glioblastoma multiforme (GBM) Gemcitabin ...

719 brain cancer management , 281–282 cancer therapy ( see Cancer therapy) cardiogenomics ( see Cardiogenomics) of epilepsy , 42 ...

720 Human immunodefi ciency virus (HIV) (cont.) gene therapy strategies , 400–401 genetic variation , 390, 391 HIV genome, struc ...

721 J Jackson Laboratory for Genomic Medicine , 619 Janus 2 tyrosine kinase (JAK2) gene , 326, 327 Johns Hopkins Kimmel Cancer C ...

722 Metabolomics (cont.) lipid profi ling , 173 urinary profi ling, capillary electrophoresis , 172–173 defi nition , 169 genoty ...

723 in genetic disorders advantages of , 530 CGH , 532 cytogenetics , 530–531 FISH with probes , 531 limitations of , 530 multip ...

724 National Cancer Institute (NCI) , 369–370, 609, 613 National Human Genome Research Institute (NHGRI) , 14, 611, 639, 683 Nat ...

725 defi nition , 580 and functional foods , 581–582 personalized medicine , 582–583 vitamin D and Ca supplementation , 581 pers ...

726 Personalized medicine (cont.) historical development of , 3–5 immune disorders ( see Immune disorders) industrial drivers , ...

727 costs of , 688 CYP isoforms , 110 defi nition , 18, 19, 99 drug addiction , 473–474 drug metabolism and pharmacological effe ...

728 Phosphatidilinositol 3-kinase/protein kinase B (PI3K-AKT) pathway , 236 Phosphatidylinositol 3 kinase (PI3K) pathway , 292–2 ...

729 biomarker , 468 EEG , 468–469 enzymes , 468 protein sFRP3, role of , 471–472 SSRI treatment , 469–471 treatment resistant de ...